SummaryThe aim of our study was to determine the factors influencing galectin-3 levels in patients with acute coronary syndrome and decreased left ventricular ejection fraction. We collected material from 37 successive patients with acute coronary syndrome and decreased left ventricular ejection fraction, of which 19 patients had atrial fibrillation, and 18 patients who were without atrial fibrillation constituted a control group. Blood samples used for the biochemical measurements were obtained on the third day from acute coronary syndrome. We used Statistical Package for Social Sciences for data analysis. A p-value less than 0.05 was considered to be a measure of statistical significance. Galectin-3 concentration is directly correlated with age and B-type natriuretic peptide level. Also, our results showed an inverse correlation between galectin-3 and total body weight, body mass index, body surface area and creatinine clearance. The following variables were found to be significant predictors of galectin-3 level: decreased left ventricular ejection fraction, total body weight, LDL concentration and body mass index. We identified factors that can predict a decrease in the left ventricular ejection fraction below 45% after acute coronary syndrome: atrial fibrillation increases the risk by almost six times, and urea concentration increases the risk by 1.2 times for each unit. Left ventricular ejection fraction below 45%, TBW, body mass index and LDL level are good predictors of galectin-3 concentration in patients with ACS and decreased left ventricular ejection fraction. Atrial fibrillation could be a predictive marker of decreased left ventricular ejection fraction.
References
1.
Sanchez-Mas J, Lax A, Asensio-Lopez MC, Fernandez-Del Palacio MJ, Caballero L, Garrido IP, et al. Galectin-3 expression in cardiac remodeling after myocardial infarction. International Journal of Cardiology. 2014;172(1):e98–101.
2.
TIAN L, CHEN K, CAO J, HAN Z, GAO L, WANG Y, et al. Galectin-3-induced oxidized low-density lipoprotein promotes the phenotypic transformation of vascular smooth muscle cells. Molecular Medicine Reports. 2015;12(4):4995–5002.
3.
Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial Fibrillation in the Setting of Acute Myocardial Infarction: The GUSTO-I Experience fn1fn1This study was funded by grants from Genentech, South San Francisco, California; Bayer Corporation, New York, New York; CIBA-Corning, Medfield, Massachusetts; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France. Journal of the American College of Cardiology. 1997;30(2):406–13.
4.
Weir RAP, Petrie CJ, Murphy CA, Clements S, Steedman T, Miller AM, et al. Galectin-3 and Cardiac Function in Survivors of Acute Myocardial Infarction. Circulation: Heart Failure. 2013;6(3):492–8.
5.
Szadkowska I, Wlazel RN, Migala M, Bajon-Laskowska K, Szadkowski K, Zielińska M, et al. The association between galectin-3 and occurrence of reinfarction early after first myocardial infarction treated invasively. Biomarkers. 2013;18(8):655–9.
6.
de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, et al. The fibrosis marker galectin‐3 and outcome in the general population. Journal of Internal Medicine. 2012;272(1):55–64.
7.
Ho JE, Yin X, Levy D, Vasan RS, Magnani JW, Ellinor PT, et al. Galectin 3 and incident atrial fibrillation in the community. American Heart Journal. 2014;167(5):729-734.e1.
8.
Grandin EW, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald E, et al. Galectin-3 and the Development of Heart Failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22. Clinical Chemistry. 2012;58(1):267–73.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
